[브릿지 칼럼] 2021년이 더 기대되는 비트코인 viva100.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from viva100.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
XPeng Announces Closing of Follow-On Public Offering and Full Exercise of the Underwriters’ Overallotment Option
December 12, 2020 GMT
GUANGZHOU, China (BUSINESS WIRE) Dec 11, 2020
XPeng Inc. (“XPeng” or the “Company”, NYSE:XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the closing of its underwritten follow-on offering of 55,200,000 American Depositary Shares (“ADSs”), each representing two Class A ordinary shares of the Company, at a public offering price of US$45.00 per ADS. The number of ADSs issued at closing included the exercise in full of the underwriters’ option to purchase 7,200,000 additional ADSs from the Company. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were approximately US$2.5 billion.
Elanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to Market marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
December 11, 2020 GMT
INDIANAPOLIS, Dec. 11, 2020 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The Phase 3 study included 1,033 patients from 67 trial sites in eight countries. These results support the emergency use authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) on Nov. 19 for baricitinib in combination with remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen.
Investegate |Heathrow Announcements | Heathrow: Publication of Final Terms investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.